{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:37:51Z","timestamp":1785253071071,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>QTc interval prolongation can result in potentially lethal arrhythmias. One risk factor is QTc-prolonging drugs, including some antifungals often used in hemato-oncology patients. Screening tools for patients at risk have not yet been investigated in this patient population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>Our aim was to evaluate the sensitivity and specificity of five QTc risk scores in hemato-oncology patients receiving systemic antifungal therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Data were retrieved from an internal study database including adult hemato-oncology patients prescribed systemic antifungal therapy. Data on QTc-prolonging medication, risk factors for QTc prolongation, and electrocardiograms (ECG) were collected retrospectively for a period of 12\u00a0months. The QTc risk scores according to Tisdale, Vandael, Berger, Bindraban, and Aboujaoude as well as their sensitivity and specificity were calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the evaluated period, 77 patients were prescribed systemic antifungals resulting in 187 therapy episodes. Regarding therapy episodes, median age was 56\u00a0years (IQR 44\u201368), 41% (77) were female, and a median of 3 QTc-prolonging drugs were prescribed (range 0\u20136). ECGs were available for 45 (24%) of the therapy episodes 3\u201311\u00a0days after initiation of the antifungal therapy, 22 of which showed QTc prolongation. Regarding these 45 therapy episodes, sensitivity and specificity of the risk scores were calculated as follows: Tisdale 86%\/22%, Vandael 91%\/35%, Berger 32%\/83%, Bindraban 50%\/78%, Aboujaoude 14%\/87%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The QTc risk scores according to Tisdale and Vandael showed sufficient sensitivity for risk stratification in the studied patient population. In contrast, risk scores according to Berger, Bindraban, and Aboujaoude cannot be considered suitable due to poor sensitivity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11096-024-01788-w","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T13:02:32Z","timestamp":1723640552000},"page":"1436-1444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Determining sensitivity and specificity of risk scores for QTc interval prolongation in hemato-oncology patients prescribed systemic antifungal therapy: a retrospective cross-sectional study"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2598-1497","authenticated-orcid":false,"given":"Julian","family":"Steinbrech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8116-129X","authenticated-orcid":false,"given":"Till","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kirschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3190-356X","authenticated-orcid":false,"given":"Hanna","family":"Mannell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5675-6128","authenticated-orcid":false,"given":"Sebastian","family":"Clau\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-6655","authenticated-orcid":false,"given":"Thilo","family":"Bertsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-0605","authenticated-orcid":false,"given":"Dorothea","family":"Strobach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"issue":"3","key":"1788_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1715163516641136","volume":"149","author":"JE Tisdale","year":"2016","unstructured":"Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149(3):139\u201352.","journal-title":"Can Pharm J (Ott)"},{"issue":"1","key":"1788_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/europace\/eut214","volume":"16","author":"G Sarganas","year":"2014","unstructured":"Sarganas G, Garbe E, Klimpel A, et al. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Europace. 2014;16(1):101\u20138.","journal-title":"Europace"},{"issue":"6","key":"1788_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199028","volume":"13","author":"FM Fernandes","year":"2018","unstructured":"Fernandes FM, Silva EP, Martins RR, et al. QTc interval prolongation in critically ill patients: prevalence, risk factors and associated medications. PLoS ONE. 2018;13(6): e0199028.","journal-title":"PLoS ONE"},{"key":"1788_CR4","unstructured":"Berul CI, Asirvatham S, Parikh N. Acquired long QT syndrome: Definitions, pathophysiology, and causes. UpToDate\u00ae. 2022. https:\/\/www.uptodate.com\/contents\/acquired-long-qt-syndrome-definitions-pathophysiology-and-causes. Accessed 04 July 2024."},{"key":"1788_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/NDT.S186474","volume":"15","author":"M Zolezzi","year":"2018","unstructured":"Zolezzi M, Cheung L. A literature-based algorithm for the assessment, management, and monitoring of drug-induced QTc prolongation in the psychiatric population. Neuropsychiatr Dis Treat. 2018;15:105\u201314.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"1788_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0002-9343(02)01455-9","volume":"114","author":"LH Curtis","year":"2003","unstructured":"Curtis LH, \u00d8stbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114(2):135\u201341.","journal-title":"Am J Med"},{"issue":"11","key":"1788_CR7","first-page":"562","volume":"76","author":"D Strobach","year":"2021","unstructured":"Strobach D, Schlattl A, Schiek S, et al. QTc-time-prolongating drugs and additional risk factors for long-QT-syndrome at hospital admission of surgical patients - risk assessment by pharmacists. Pharmazie. 2021;76(11):562\u20136.","journal-title":"Pharmazie"},{"issue":"3","key":"1788_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40801-021-00234-x","volume":"8","author":"M Rossi","year":"2021","unstructured":"Rossi M, Marzi F, Natale M, et al. Drug-associated QTc prolongation in geriatric hospitalized patients: a cross-sectional study in internal medicine. Drugs Real World Outcomes. 2021;8(3):325\u201335.","journal-title":"Drugs Real World Outcomes"},{"issue":"1108","key":"1788_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/postgradmedj-2017-135208","volume":"94","author":"JJ Coughlan","year":"2018","unstructured":"Coughlan JJ, Wafer M, Fitzgerald G, et al. QTc prolongation in acute medical admissions: an often overlooked and potentially serious finding. Postgrad Med J. 2018;94(1108):123\u20134.","journal-title":"Postgrad Med J"},{"issue":"8","key":"1788_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/phar.2146","volume":"38","author":"E Tomaselli Muensterman","year":"2018","unstructured":"Tomaselli Muensterman E, Tisdale JE. Predictive analytics for identification of patients at risk for QT interval prolongation: a systematic review. Pharmacotherapy. 2018;38(8):813\u201321.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"1788_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/01.md.0000085057.63483.9b","volume":"82","author":"D Zeltser","year":"2003","unstructured":"Zeltser D, Justo D, Halkin A, et al. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore). 2003;82(4):282\u201390.","journal-title":"Medicine (Baltimore)"},{"key":"1788_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/annonc\/mdt266","volume":"24","author":"L Balducci","year":"2013","unstructured":"Balducci L, Goetz-Parten D, Steinman MA. Polypharmacy and the management of the older cancer patient. Ann Oncol. 2013;24:36\u201340.","journal-title":"Ann Oncol"},{"issue":"1","key":"1788_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jgo.2011.11.004","volume":"3","author":"M Extermann","year":"2012","unstructured":"Extermann M, Wedding U. Comorbidity and geriatric assessment for older patients with hematologic malignancies: a review of the evidence. J Geriatr Oncol. 2012;3(1):49\u201357.","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"1788_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaccao.2021.01.002","volume":"3","author":"PY Kim","year":"2021","unstructured":"Kim PY, Irizarry-Caro JA, Ramesh T, et al. How to diagnose and manage QT prolongation in cancer patients. JACC CardioOncol. 2021;3(1):145\u20139.","journal-title":"JACC CardioOncol"},{"key":"1788_CR15","unstructured":"Woosley RL, Heise CW, Gallo T et al. QTdrugs List. AZCERT, Inc. 1457 E. Desert Garden Dr., Tucson, AZ 85718 www.CredibleMeds.org. Accessed 04 July 2024."},{"key":"1788_CR16","unstructured":"Mellinghoff S, Alakel N, Behre G et al. Antimykotische Prim\u00e4rprophylaxe bei Patienten mit h\u00e4matologischen Neoplasien. Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e.V. Berlin. 2018. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/antimykotische-primaerprophylaxe-bei-patienten-mit-haematologischen-neoplasien\/@@guideline\/html\/index.html. Accessed 04 July 2024."},{"key":"1788_CR17","unstructured":"Ruhnke M, Cornely OA, Schmidt-Hieber M et al. Invasive Pilzinfektionen \u2013 Therapie. Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e.V. Berlin. 2020. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/invasive-pilzinfektionen-therapie\/@@guideline\/html\/index.html. Accessed 04 July 2024."},{"issue":"5","key":"1788_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00228-022-03285-3","volume":"78","author":"S Skullbacka","year":"2022","unstructured":"Skullbacka S, Airaksinen M, Puustinen J, et al. Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review. Eur J Clin Pharmacol. 2022;78(5):765\u201379.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1788_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11096-017-0446-2","volume":"39","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J, et al. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424\u201332.","journal-title":"Int J Clin Pharm"},{"key":"1788_CR20","doi-asserted-by":"publisher","unstructured":"Aboujaoude E, Mathew J, Sobocinski S et al. Development and validation of a QTc-prolongation risk score to optimize interruptive medication alerts. Authorea. 2021 [preprint]; https:\/\/doi.org\/10.22541\/au.163879967.78380326\/v1","DOI":"10.22541\/au.163879967.78380326\/v1"},{"issue":"12","key":"1788_CR21","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1111\/bcp.13740","volume":"84","author":"E Vandael","year":"2018","unstructured":"Vandael E, Vandenberk B, Vandenberghe J, et al. A smart algorithm for the prevention and risk management of QTc prolongation based on the optimized RISQ-PATH model. Br J Clin Pharmacol. 2018;84(12):2824\u201335.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1788_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12911-020-01181-3","volume":"20","author":"FA Berger","year":"2020","unstructured":"Berger FA, van der Sijs H, Becker ML, et al. Development and validation of a tool to assess the risk of QT drug-drug interactions in clinical practice. BMC Med Inform Decis Mak. 2020;20(1):171.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"5","key":"1788_CR23","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s11096-018-0692-y","volume":"40","author":"AN Bindraban","year":"2018","unstructured":"Bindraban AN, Rolvink J, Berger FA, et al. Development of a risk model for predicting QTc interval prolongation in patients using QTc-prolonging drugs. Int J Clin Pharm. 2018;40(5):1372\u20139.","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"1788_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.mayocp.2013.01.013","volume":"88","author":"KH Haugaa","year":"2013","unstructured":"Haugaa KH, Bos JM, Tarrell RF, et al. Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc. 2013;88(4):315\u201325.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"1788_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4258\/hir.2021.27.3.182","volume":"27","author":"TY Kim","year":"2021","unstructured":"Kim TY, Choi BJ, Koo Y, et al. Development of a risk score for QT prolongation in the intensive care unit using time-series electrocardiogram data and electronic medical records. Healthc Inform Res. 2021;27(3):182\u20138.","journal-title":"Healthc Inform Res"},{"issue":"4","key":"1788_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1074248421995348","volume":"26","author":"ST Simon","year":"2021","unstructured":"Simon ST, Mandair D, Tiwari P, et al. Prediction of drug-induced long QT syndrome using machine learning applied to harmonized electronic health record data. J Cardiovasc Pharmacol Ther. 2021;26(4):335\u201340.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"1788_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","volume":"6","author":"JE Tisdale","year":"2013","unstructured":"Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479\u201387.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"1788_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1161\/CIRCOUTCOMES.113.000651","volume":"7","author":"JE Tisdale","year":"2014","unstructured":"Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2014;7(3):381\u201390.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"1788_CR29","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/0018578720965429","volume":"56","author":"B Newell","year":"2021","unstructured":"Newell B, Wirick N, Rigelsky F, et al. Implementation of a pharmacist monitoring process for patients on QTc prolonging antibiotics: a pilot study. Hosp Pharm. 2021;56(6):772\u20136.","journal-title":"Hosp Pharm"},{"key":"1788_CR30","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1093\/ajhp\/zxaa269","volume":"77","author":"K Chernoby","year":"2020","unstructured":"Chernoby K, Lucey MF, Hartner CL, et al. Impact of a clinical decision support tool targeting QT-prolonging medications. Am J Health Syst Pharm. 2020;77:S111\u20137.","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"1788_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1542-474X.1997.tb00325.x","volume":"2","author":"HC Bazett","year":"1997","unstructured":"Bazett HC. An analysis of the time-relations of electrocardiograms. Ann Noninvasive Electrocardiol. 1997;2(2):177\u201394.","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"1788_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2020.104329","volume":"145","author":"FA Berger","year":"2012","unstructured":"Berger FA, van der Sijs H, van Gelder T, et al. Comparison of two algorithms to support medication surveillance for drug-drug interactions between QTc-prolonging drugs. Int J Med Inform. 2012;145: 104329.","journal-title":"Int J Med Inform"},{"issue":"6","key":"1788_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127213","volume":"10","author":"A Poncet","year":"2015","unstructured":"Poncet A, Gencer B, Blondon M, et al. Electrocardiographic screening for prolonged QT interval to reduce sudden cardiac death in psychiatric patients: a cost-effectiveness analysis. PLoS ONE. 2015;10(6): e0127213.","journal-title":"PLoS ONE"},{"key":"1788_CR34","doi-asserted-by":"publisher","first-page":"1039867","DOI":"10.3389\/fphar.2022.1039867","volume":"13","author":"J Zhou","year":"2022","unstructured":"Zhou J, Wei Z, Xu B, et al. Pharmacovigilance of triazole antifungal agents: analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2022;13:1039867.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1788_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/myc.12731","volume":"61","author":"SC Mellinghoff","year":"2018","unstructured":"Mellinghoff SC, Bassetti M, D\u00f6rfel D, et al. Isavuconazole shortens the QTc interval. Mycoses. 2018;61(4):256\u201360.","journal-title":"Mycoses"},{"issue":"6","key":"1788_CR36","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/cpt.620","volume":"101","author":"J Keirns","year":"2017","unstructured":"Keirns J, Desai A, Kowalski D, et al. QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization. Clin Pharmacol Ther. 2017;101(6):782\u201390.","journal-title":"Clin Pharmacol Ther"},{"issue":"41","key":"1788_CR37","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, ESC Scientific Document Group, et al. ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"10","key":"1788_CR38","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s40264-022-01215-x","volume":"45","author":"M Putnikovic","year":"2022","unstructured":"Putnikovic M, Jordan Z, Munn Z, et al. Use of electrocardiogram monitoring in adult patients taking high-risk QT interval prolonging medicines in clinical practice: systematic review and meta-analysis. Drug Saf. 2022;45(10):1037\u201348.","journal-title":"Drug Saf"},{"issue":"3","key":"1788_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2174\/1573403X10666140514103612","volume":"10","author":"PG Postema","year":"2014","unstructured":"Postema PG, Wilde AA. The measurement of the QT interval. Curr Cardiol Rev. 2014;10(3):287\u201394.","journal-title":"Curr Cardiol Rev"},{"issue":"6","key":"1788_CR40","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.hrthm.2005.02.011","volume":"2","author":"S Viskin","year":"2005","unstructured":"Viskin S, Rosovski U, Sands AJ, et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm. 2005;2(6):569\u201374.","journal-title":"Heart Rhythm"},{"issue":"7","key":"1788_CR41","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.hrthm.2008.03.037","volume":"5","author":"PG Postema","year":"2008","unstructured":"Postema PG, De Jong JS, Van der Bilt IA, et al. Accurate electrocardiographic assessment of the QT interval: teach the tangent. Heart Rhythm. 2008;5(7):1015\u20138.","journal-title":"Heart Rhythm"},{"issue":"3","key":"1788_CR42","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ccl.2006.03.005","volume":"24","author":"RH Hongo","year":"2006","unstructured":"Hongo RH, Goldschlager N. Status of computerized electrocardiography. Cardiol Clin. 2006;24(3):491\u2013504.","journal-title":"Cardiol Clin"},{"issue":"1","key":"1788_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/s-0041-1740483","volume":"13","author":"S Stettner","year":"2022","unstructured":"Stettner S, Adie S, Hanigan S, et al. Effect of replacing vendor QTc alerts with a custom QTc risk alert in inpatients. Appl Clin Inform. 2022;13(1):19\u201329.","journal-title":"Appl Clin Inform"},{"issue":"3","key":"1788_CR44","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s11096-024-01703-3","volume":"46","author":"P Li","year":"2024","unstructured":"Li P, Zhu M, Gao A, et al. A case-control study on the clinical characteristics of granisetron-related arrhythmias and the development of a predictive nomogram. Int J Clin Pharm. 2024;46(3):684\u201393.","journal-title":"Int J Clin Pharm"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01788-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:08:59Z","timestamp":1732068539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01788-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1788"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01788-w","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}